食管癌放疗后新发心房颤动及其与生存结局的关系
该研究基于2007至2019年间连续接受胸部放疗的238例食管癌患者,评估新发心房颤动(AF)的发生率与结局。结果显示21.4%发生新发AF,33%发生主要不良心血管事件(MACE),84%事件发生于放疗启动后2年内;AF发生率显著高于Framingham预测值(相对风险8.96,P<.001),左心房放疗剂量增高与AF强相关(P=.001),AF者疾病进展风险更高(HR 1.54,P=.03)。
要点
- 238例食管癌胸部放疗患者中,21.4%发生新发AF,33%发生MACE,84%事件发生于放疗启动后2年内。
- 观察到的AF发生率为每10000人年824例,Framingham预测率为92(相对风险8.96;P<.001;绝对超额风险732)。
- 左心房放疗剂量增高与AF发生强相关(P=.001),且AF者疾病进展风险更高(HR 1.54;P=.03)。
核心结论
- 在食管癌患者中,放疗增加AF风险,并与更差的长期结局相关。
研究设计与样本
- 研究利用2007至2019年间连续接受胸部放疗的食管癌患者大型队列,评估新发AF的发生率与结局。
- 次要结局为按心脏放疗剂量评估的MACE,定义为AF、心力衰竭、室性心律失常和猝死。
- 研究评估AF发生与无进展生存和总生存的关系,将观察到的AF发生率与Framingham预测率比较并估算绝对超额风险。
- 采用多变量回归定义临床与放疗指标和结局的关系,并通过30天界标分析评估按AF状态分组的结局差异。
- 研究评估心脏亚结构(如左心房)放疗剂量对放疗后结局风险的影响。
主要发现
- 238例接受放疗的食管癌患者中,21.4%发生新发AF,33%发生MACE,其中多数(84%)事件发生于放疗启动后≤2年(至AF的中位时间4.1个月)。
- 1年时AF和MACE的累积发生率分别为19.5%和25.7%。
- 观察到的AF发生率为每10000人年824例,Framingham预测率为92(相对风险8.96;P<.001;绝对超额风险732)。
- 左心房剂量增高与AF发生强相关(P=.001);发生AF者疾病进展更差(风险比1.54;P=.03)。
- 多变量模型中,除传统癌症相关因素外,左心房放疗剂量增高仍与更差的总生存相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy (RT) associates with long-term cardiotoxicity. In preclinical models, RT exposure induces early cardiotoxic arrhythmias including atrial fibrillation (AF). Yet, whether this occurs in patients is unknown. METHODS AND MATERIALS: Leveraging a large cohort of consecutive patients with esophageal cancer treated with thoracic RT from 2007 to 2019, we assessed incidence and outcomes of incident AF. Secondary outcomes included major adverse cardiovascular events (MACE), defined as AF, heart failure, ventricular arrhythmias, and sudden death, by cardiac RT dose. We also assessed the relationship between AF development and progression-free and overall survival. Observed incident AF rates were compared with Framingham predicted rates, and absolute excess risks were estimated. Multivariate regression was used to define the relationship between clinical and RT measures, and outcomes. Differences in outcomes, by AF status, were also evaluated via 30-day landmark analysis. Furthermore, we assessed the effect of cardiac substructure RT dose (eg, left atrium, LA) on the risk of post RT-related outcomes. RESULTS: Overall, from 238 RT treated patients with esophageal cancer, 21.4% developed incident AF, and 33% developed MACE with the majority (84%) of events occurring ≤2 years of RT initiation (median time to AF, 4.1 months). Cumulative incidence of AF and MACE at 1 year was 19.5%, and 25.7%, respectively; translating into an observed incident AF rate of 824 per 10,000 person-years, compared with the Framingham predicted rate of 92 (relative risk, 8.96; P < .001, absolute excess risk 732). Increasing LA dose strongly associated with incident AF (P = .001); and those with AF saw worse disease progression (hazard ratio, 1.54; P = .03). In multivariate models, outside of traditional cancer-related factors, increasing RT dose to the LA remained associated with worse overall survival. CONCLUSIONS: Among patients with esophageal cancer, radiation therapy increases AF risk, and associates with worse long-term outcomes.
引用
- Miller ED, Wu T, McKinley G, et al. Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following Radiotherapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 37574171. doi:10.1016/j.ijrobp.2023.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。